ERBB2 and cancer: These monoclonal antibodies frequently have limited effectiveness in combating cancers as tumor cells circumvent the action of the single agents due to the readjustments in co-expression of HER2/HER3 receptors, their ligand binding dynamics or changing preference for the dimerizing partners [25, 34, 35].